OncoMatch/Clinical Trials/NCT04516681
Combination of IV Ascorbic Acid and Adebrelimab in Metastatic Colorectal Cancer
Is NCT04516681 recruiting? Yes, currently enrolling (May 2026). This Phase 3 trial studies multiple treatments including Ascorbic acid and FOLFOX Protocol for colorectal cancer.
Treatment: Ascorbic acid · FOLFOX Protocol · Adebrelimab — Previous preclinical study has shown that high levels of ascorbic acid (AA) possesses the ability to kill human colorectal cancer cells and high expression of GLUT3 will augment the efficacy of AA. To date, no previous studies have investigated the combination of therapeutic role of AA and PD-L1 antibody in metastatic colorectal cancer with high expression of GLUT3. This protocol is a randomized controlled study of AA infusions combined with Adebrelimab and FOLFOX +/- bevacizumab versus treatment with FOLFOX +/- bevacizumab alone in metastatic colorectal cancer patients with high expression of GLUT3.
Check if I qualifyExtracted eligibility criteria
Cancer type
Colorectal Cancer
Biomarker criteria
Required: SLC2A3 strong positive (strong positive)
IHC confirmed strong positive GLUT3
Excluded: SLC2A3 low or moderate expression
Patients with low or moderate expression of GLUT3 [excluded]
Disease stage
Metastatic disease required
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy for metastatic disease
Exception: adjuvant therapy with fluoropyrimidines +/- oxaliplatin based regimens allowed if stopped 12 months prior to registration on study
Prior treatment for metastatic disease (adjuvant therapy with fluoropyrimidines +/-oxaliplatin based regimens allowed if stopped 12 months prior to registration on study)
Lab requirements
Blood counts
ANC ≥1,500/mm3; Hemoglobin > 8g/dL; platelet ≥ 100,000/mm3
Kidney function
creatinine ≤1.5X ULN; if elevated but ≤1.5X ULN, CrCl > 50 mL/min (Cockroft and Gault)
Liver function
Transaminase (AST/ALT) ≤2.5X ULN and bilirubin ≤1.5X ULN without liver metastasis; AST/ALT ≤5X ULN and bilirubin ≤1.5X ULN with liver metastasis
ANC ≥1,500/mm3; Hemoglobin > 8g/dL; platelet ≥ 100,000/mm3; creatinine ≤1.5X ULN; if elevated but ≤1.5X ULN, CrCl > 50 mL/min (Cockroft and Gault); AST/ALT ≤2.5X ULN and bilirubin ≤1.5X ULN without liver metastasis; AST/ALT ≤5X ULN and bilirubin ≤1.5X ULN with liver metastasis
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify